GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Return-on-Tangible-Asset
中文

Bionano Genomics (Bionano Genomics) Return-on-Tangible-Asset : -107.52% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bionano Genomics's annualized Net Income for the quarter that ended in Dec. 2023 was $-175.56 Mil. Bionano Genomics's average total tangible assets for the quarter that ended in Dec. 2023 was $163.29 Mil. Therefore, Bionano Genomics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -107.52%.

The historical rank and industry rank for Bionano Genomics's Return-on-Tangible-Asset or its related term are showing as below:

BNGO' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -187.42   Med: -107.13   Max: -41.88
Current: -137.13

During the past 8 years, Bionano Genomics's highest Return-on-Tangible-Asset was -41.88%. The lowest was -187.42%. And the median was -107.13%.

BNGO's Return-on-Tangible-Asset is ranked worse than
90.75% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -2.31 vs BNGO: -137.13

Bionano Genomics Return-on-Tangible-Asset Historical Data

The historical data trend for Bionano Genomics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Return-on-Tangible-Asset Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -108.40 -100.25 -41.88 -54.89 -125.84

Bionano Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.34 -81.46 -93.75 -297.52 -107.52

Competitive Comparison of Bionano Genomics's Return-on-Tangible-Asset

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Return-on-Tangible-Asset falls into.



Bionano Genomics Return-on-Tangible-Asset Calculation

Bionano Genomics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-232.493/( (189.072+180.432)/ 2 )
=-232.493/184.752
=-125.84 %

Bionano Genomics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-175.564/( (146.138+180.432)/ 2 )
=-175.564/163.285
=-107.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Bionano Genomics  (NAS:BNGO) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Bionano Genomics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.
Executives
Gulsen Kama officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin director, officer: President and CEO 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon officer: General Counsel C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic director 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams officer: Chief Informatics Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy officer: Chief Business Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar officer: Chief Commercial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey officer: Chief Medical Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams officer: Chief Administrative Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011

Bionano Genomics (Bionano Genomics) Headlines

From GuruFocus